---
title: "Gan & Lee: The first subject has been dosed in the Phase II clinical trial of GZR102 injection"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252174397.md"
description: "Gan & Lee Pharmaceuticals announced that its wholly-owned subsidiary has successfully completed the administration of the first subject in the Phase II clinical trial of GZR102 injection. GZR102 is a fixed-ratio combination weekly formulation of basal insulin/GLP-1RA, designed to provide an effective and safe combination therapy for patients with type 2 diabetes. The drug maximizes the synergistic effect of the two medications through an innovative formulation, and is expected to enhance glycemic control while reducing adverse reactions"
datetime: "2025-08-08T07:37:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252174397.md)
  - [en](https://longbridge.com/en/news/252174397.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252174397.md)
---

# Gan & Lee: The first subject has been dosed in the Phase II clinical trial of GZR102 injection

According to the Zhitong Finance APP, Gan & Lee (603087.SH) announced that its wholly-owned subsidiary Gan & Lee Pharmaceutical Shandong Co., Ltd. has independently developed GZR102 injection, which is currently undergoing Phase II clinical trials in China, and has recently successfully completed the first administration to a subject.

GZR102 injection is a fixed-ratio combination weekly formulation of basal insulin/GLP-1RA, composed of the insulin weekly formulation GZR4 and the GLP-1RA Bofaglutide in a fixed ratio. As a once-weekly subcutaneous injection formulation, GZR102 injection maximizes the synergistic effect of the two drug components through an innovative formulation. The combination therapy of GLP-1RA and insulin can address multiple pathophysiological defects of type 2 diabetes, enhancing glucose-lowering effects while reducing daily insulin dosage, and minimizing adverse reactions such as hypoglycemia and weight gain, potentially providing an effective, safe, and convenient combination therapy option for patients with type 2 diabetes. Currently, the global development of GZR102 has entered the Phase II clinical stage

### Related Stocks

- [603087.CN](https://longbridge.com/en/quote/603087.CN.md)

## Related News & Research

- [15:48 ETTareen Development Partners Completes $12.75 Million Sale of Eagan Medical Center](https://longbridge.com/en/news/296263550.md)
- [13:11 ETFrom Caregiver Perspectives to Clinical Trial Design: Advancing Community-Engaged Autism Research](https://longbridge.com/en/news/296255869.md)
- [10:30 ETInventHelp Inventor Develops Improved Hospital Gown (TLS-1385)](https://longbridge.com/en/news/296121131.md)
- [Max Power to present Lawson natural hydrogen discovery at IMAGE ’26 in Houston](https://longbridge.com/en/news/296226273.md)
- [13:22 ET/C O R R E C T I O N -- Rayence/](https://longbridge.com/en/news/296256530.md)